Related Experiment Videos
[Effects of Tilade in asthma].
1Clinique des Maladies Respiratoires, Hôpital Universitaire Aiguelongue, Montpellier.
Revue Des Maladies Respiratoires
|January 1, 1992
Summary
Nedocromil effectively reduces asthma symptoms and bronchial hyperresponsiveness. Clinical studies show it improves lung function and reduces the need for rescue inhalers, offering a promising treatment option.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Trials
Background:
- Nedocromil is an anti-inflammatory agent used for asthma management.
- Its efficacy is demonstrated through inhibition of various asthma triggers and reduction of bronchial hyperresponsiveness.
Purpose of the Study:
- To evaluate the clinical effectiveness of nedocromil in asthma patients.
- To assess nedocromil's impact on asthma symptoms, lung function, and medication requirements.
Main Methods:
- Review of clinical studies investigating nedocromil's effects.
- Analysis of data from single-dose and chronic administration studies.
- Comparison with placebo in international trials.
Main Results:
- Nedocromil inhibits responses to diverse stimuli including adenosine, SO2, cold air, and exercise.
- Chronic administration diminishes bronchial hyperresponsiveness.
- Studies reported improved asthma symptoms, PEFR, FEV1, and reduced need for beta-2-sympathomimetics and oral steroids.
Conclusions:
- Nedocromil is a viable long-term treatment for mild asthma, allergic or non-allergic.
- It can improve symptoms in moderate asthma and reduce steroid dependency in severe cases.
- Development of improved delivery systems and formulations for nedocromil is warranted.